Haleon plc (NYSE:HLN) Shares Bought by Allworth Financial LP

Allworth Financial LP grew its stake in Haleon plc (NYSE:HLN) by 31.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 9,884 shares of the company’s stock after buying an additional 2,383 shares during the quarter. Allworth Financial LP’s holdings in Haleon were worth $90,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Lake Street Advisors Group LLC lifted its stake in Haleon by 5.4% in the 3rd quarter. Lake Street Advisors Group LLC now owns 22,395 shares of the company’s stock valued at $237,000 after buying an additional 1,143 shares in the last quarter. Synovus Financial Corp lifted its position in Haleon by 0.8% during the 3rd quarter. Synovus Financial Corp now owns 148,834 shares of the company’s stock worth $1,575,000 after acquiring an additional 1,216 shares in the last quarter. Greenleaf Trust grew its stake in shares of Haleon by 8.4% during the fourth quarter. Greenleaf Trust now owns 17,225 shares of the company’s stock valued at $164,000 after acquiring an additional 1,333 shares in the last quarter. Baron Wealth Management LLC increased its holdings in Haleon by 4.3% during the 4th quarter. Baron Wealth Management LLC now owns 33,632 shares of the company’s stock worth $321,000 after purchasing an additional 1,381 shares during the last quarter. Finally, Peapack Gladstone Financial Corp increased its holdings in Haleon by 3.2% in the third quarter. Peapack Gladstone Financial Corp now owns 44,844 shares of the company’s stock valued at $474,000 after buying an additional 1,390 shares during the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on HLN shares. Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.95.

Haleon Trading Up 0.6 %

NYSE HLN opened at $10.15 on Tuesday. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The firm has a market capitalization of $45.93 billion, a P/E ratio of 29.84, a PEG ratio of 2.82 and a beta of 0.28. The business has a fifty day simple moving average of $9.57 and a 200 day simple moving average of $9.83. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.